Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.47 |
| ▸ | NQO2 | P16083 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28059088 | 0.83 | CYP19A1 (0.48) | ALDH1A1KDM4EHPGDLMNACYP19A1 | |
| SCHEMBL13344922 | 0.77 | KDM4E (0.58) | ALDH1A1KDM4EHPGDLMNACYP19A1 | |
| SCHEMBL26660799 | 0.76 | CYP2A6 (0.37) | ALDH1A1KDM4EHPGDLMNANQO2 | |
| SCHEMBL31501965 | 0.76 | CYP2A6 (0.37) | ALDH1A1KDM4EHPGDLMNANQO2 | |
| SCHEMBL13946720 | 0.75 | EHMT2 (0.55) | ALDH1A1KDM4EHPGDSMN1; SMN2GRIN2D | |
| SCHEMBL27518825 | 0.75 | KDM4E (0.57) | ALDH1A1KDM4EHPGDLMNACYP19A1 | |
| SCHEMBL14234928 | 0.75 | KDM4E (0.57) | ALDH1A1KDM4EHPGDLMNACYP19A1 | |
| SCHEMBL3558749 | 0.75 | KDM4E (0.56) | ALDH1A1KDM4EHPGDLMNACYP19A1 | |
| SCHEMBL20920169 | 0.75 | ALDH1A1 (0.49) | ALDH1A1KDM4EHPGDLMNANQO2 | |
| SCHEMBL27566870 | 0.75 | KMT2A (0.44) | ALDH1A1KDM4EHPGDLMNACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113439084-A | Duocarmycin analogs | 奥克兰联合服务有限公司 | 2021-09-24 | — | — | CN | disclosed |
| CN-102432522-B | Method for preparing substituted 2-indolinone compound | UNIV PLA 2ND MILITARY MEDICAL | 2014-04-02 | — | — | CN | disclosed |
| CN-101044114-B | Nitrobenzindoles and their use in cancer therapy | AUCKLAND UNISERVICES LTD. (NZ) | 2012-02-15 | — | — | CN | disclosed |
| US-7718688-B2 | Nitrobenzindoles and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-18 | — | — | US | disclosed |
| EP-1809603-A4 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2009-09-02 | — | — | EP | disclosed |
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-05-22 | — | — | US | disclosed |
| EP-1809603-A1 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | Auckland Uniservices Limited (NZ) | 2007-07-25 | — | — | EP | disclosed |
| CN-1281585-C | Cyclic diamine compounds having fused-ring groups | KOWA CO (JP) | 2006-10-25 | — | — | CN | disclosed |
| WO-2006043839-A1 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2006-04-27 | — | — | WO | disclosed |
| CN-1599717-A | Cyclic diamine compounds having fused-ring groups | KOWA CO (JP) | 2005-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | HIF1AN, HYOU1, HIF1A | ALDH1A1 77/4885KDM4E 856/4885HPGD 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.